pLOG

2025-05-16

**Latest Release from PATIENT VIEW: 2025 Global Survey on Patient Groups’ Perceptions of the Pharmaceutical Industry’s Reputation**

The 2024/2025 corporate reputation survey was conducted between December 2024 and March 2025, gathering responses from 2,546 patient groups across 100 countries—a record high. This milestone underscores the growing voice and influence of the patient community within the healthcare ecosystem. Each year, PatientView surveys patient groups across various disease areas and regions, focusing not on scientific data or profits, but on how well companies build trust and partnerships with patients.

Fame and Trust: Not One and the Same

The report focuses on two key indicators: Familiarity and Partnerships. In theory, these two should correlate—but the data reveals a more nuanced reality.

Take Pfizer, for example. It ranks highest in familiarity, with 1,664 mentions, and also leads in reported collaborations with patient groups, cited 932 times. Roche and Novartis show a similar dual-strong performance, demonstrating that when companies prioritize patient engagement, they not only gain visibility but also earn trust.

In contrast, AbbVie and Amgen, despite being highly recognized (with 1,012 and 790 mentions respectively), show a relatively lower number of reported partnerships, suggesting that familiarity does not automatically translate into trusted collaboration.

 

Small Companies, Big Trust: Niche Strategies That Work

Several smaller or disease-focused companies—such as Vertex, UCB, and Servier—stood out for their performance. While their overall familiarity scores were lower, their partnership ratios were notably high.

This highlights a key insight: patient communities increasingly value genuine engagement over brand size. Even with limited resources, companies that invest in building authentic, long-term relationships can earn lasting trust and loyalty.

 

How Should Pharmaceutical Companies Respond?

This report not only highlights the issues but also offers directions for improvement:

  • Invest in genuine partnerships rather than just marketing campaigns.
  • Truly listen to patients’ voices during both development and launch phases.
  • Promote inclusion programs that involve patients with rare and marginalized diseases.
  • Incorporate "patient trust" as a key performance indicator (KPI).

 

Summary

The reputation of pharmaceutical companies in 2024 is not determined by who has the loudest voice, but by who listens most attentively. Trust and familiarity are no longer innate—they must be built through continuous dialogue, collaboration, and action.

Pharmaceutical companies that want to succeed in the future healthcare landscape must transform from mere product suppliers into true patient partners. As this report shows, patients are watching—and waiting for your response.